Faites connaître cette offre !
Reference : UMR5237-SERROC-005
Workplace : MONTPELLIER
Date of publication : Friday, February 19, 2021
Type of Contract : FTC Scientist
Contract Period : 18 months
Expected date of employment : 1 April 2021
Proportion of work : Full time
Remuneration : remuneration for the IR level of the CNRS grids
Desired level of education : PhD
Experience required : 1 to 4 years
The "tyrosine kinases and cancer" team aims to understand the role of tyrosine kinases in cancer aggressiveness. The research program concerns the development of a new therapy targeting the microenvironment of colon tumors. The candidate will finalize the understanding of the mechanism involved and the development of this original therapy
--provide experimental evidence supporting the mechanism studied from in vitro models of cell culture and tumorides and in vivo models of xenografts in immunosuppressed mice
-assess the anti-cancer activity of the antibodies blocking this process on the models developed
-evaluate their mechanisms of action
doctoral level experience in cellular and molecular biology
- doctoral level competence in cancer biology
-experience in cell signaling desired
-experiment on the development of tumor models in immunocompromised mice desired
-experience in the development of therapeutic antibodies is a plus
The position is open in the “tyrosine kinases and cancer” team at the Montpellier Cellular Biology Research Center. The team is trying to understand the mechanisms behind tumor aggressiveness. The project aims to target the tumor microenvironment as a new therapeutic strategy in metastatic colorectal cancer. The team (http://www.crbm.cnrs.fr/team/tyrosine-kinases-cancer/) is part of the Montpellier Cellular Biology Research Center (CRBM; http://www.crbm.cnrs.fr ). The CRBM, which is under the supervision of the CNRS and the University of Montpellier, is located on the CNRS campus, route de Mende, in Montpellier.
This project is in collaboration with 2 "cancer" teams from CNRS and INSERM Montpellier
We talk about it on Twitter!